Erin M. Lavelle
Independent DirectorMs. Erin M. Lavelle is Independent Director of LTZ Therapeutics Inc. from May 2026. Ms. Lavelle is Independent Director of Expedition Therapeutics Inc. Ms. Lavelle is an Independent Director of Jade Biosciences, Inc. since September 2024 and is also a Director at Aviceda Therapeutics, Inc. Ms. Lavelle is Independent Director of Avalyn Pharma Inc. from July 2024. She is former chief operating officer and chief financial officer of ProfoundBio Inc from October 2023 to July 2024. She serves as Director at Rivus Pharmaceuticals, Inc. since September 2024. She served as an Executive Vice President, Chief Operating Officer & Chief Financial Officer at Climb Bio, Inc. (formerly Eliem Therapeutics, Inc.). since October 2020 until March 2023. She served as an Independent Director at Neoleukin Therapeutics Inc. which later became Neurogene Inc., from May 2020 to December 2023. She has served as the Chief Operating Officer and Chief Financial Officer Eliem Therapeutics since October 2020. Prior to joining Eliem, Ms. Lavelle served as Chief Operating Officer of Alder Biopharmaceuticals, Inc. since April 16, 2018 until February 2020. In addition to that role, she served as Alder appointed Director for Vitaeris Inc. Ms. Lavelle served as the General Manager of Amgen’s Taiwan affiliate from September 2017 to April 2018, where she was responsible for managing a portfolio of six commercialized products and leading a team of 80 cross-functional colleagues. She was an Executive Director of Japan Asia Pacific (Hong Kong) from May2016 to September 2017. Ms. Lavelle was based in Hong Kong as an Executive Director for the Japan Asia-Pacific region from May 2016 to September 2017 and Executive Director, Global Marketing Business Analytics and Insights from June 2014 to May 2016. Ms. Lavelle has strategic and operational leadership experience in the biopharmaceutical industry and served as Chief Operating Officer for Alder Biopharmaceuticals, Inc. from April 2018 to February 2020. Ms. Lavelle joined Alder in April 2018 to focus on operational initiatives preparing the company for its first product launch. Prior to Alder, she held a variety of roles at Amgen Inc. from 2003 to 2018. From July 2003 to June 2016, she held roles as Executive Director in the areas of Global Marketing, Global Commercial Finance and Strategy and Corporate Development. Ms. Lavelle began her career in 1998 as an investment banker in the healthcare group at Merrill Lynch & Co. Ms. Lavelle holds a Bachelor of Arts in Economics from Yale University.
Positions
- Company NameJade Biosciences, Inc.Stock CodeJBIOPositionIndependent DirectorColleagues
- TFTom FrohlichPresident, CEO & Director
- ELEric L. DobmeierIndependent Chairman
- BDBradford D. DahmsCFO and Chief Business Officer
- AJAndrew James KingPresident of Research & Development
- EBElizabeth BaltaChief Legal Officer & Corporate Secretary
- LSLori StewartSenior Vice President of People
- TKTomas KiselakIndependent Director
- LOLawrence Otto KleinIndependent Director
- EMErin M. LavelleIndependent Director
- Company NameAvalyn Pharma Inc.Stock CodeAVLNPositionIndependent DirectorColleagues
- LBLyn BaranowskiCEO, President & Director
- HDHeather D. TurnerIndependent Chairman
- DRDouglas R. CarlsonCFO & Chief Business Officer
- MRMelissa RhodesChief Operating Officer
- HMHoward M. LazarusChief Medical Officer
- CSCassie SaitowSenior Director of IR & Corporate Communications
- JCJill CarrollIndependent Director
- KHKathryn HavilandIndependent Director
